Related Experiment Video
Updated: Mar 26, 2026

Glycomics-Guided Glycoproteomics Facilitates Comprehensive Profiling of the Glycoproteome in Complex Tumor Microenvironments
Published on: February 7, 2025
Glyco-nano-oncology: Novel therapeutic opportunities by combining small and sweet
Pablo F Hockl1, Alejandro Wolosiuk2, Juan M Pérez-Sáez1
1Laboratorio de Inmunopatología, Instituto de Biología y Medicina Experimental (IBYME), Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Vuelta de Obligado 2490, C1428ADN Buenos Aires, Argentina.
Abstract:
Recent efforts toward defining the molecular features of the tumor microenvironment have revealed dramatic changes in the expression of glycan-related genes including glycosyltransferases and glycosidases. These changes affect glycosylation of proteins and lipids not only in cancer cells themselves, but also in cancer associated-stromal, endothelial and immune cells. These glycan alterations including increased frequency of β1,6-branched N-glycans and bisecting N-glycans, overexpression of tumor-associated mucins, preferred expression of T, Tn and sialyl-Tn antigen and altered surface sialylation, may contribute to tumor progression by masking or unmasking specific ligands for endogenous lectins, including members of the C-type lectin, siglec and galectin families. Differential expression of glycans or glycan-binding proteins could be capitalized for the identification of novel biomarkers and might provide novel opportunities for therapeutic intervention. This review focuses on the biological relevance of lectin-glycan interactions in the tumor microenvironment (mainly illustrated by the immunosuppressive and pro-angiogenic activities of galectin-1) and the design of functionalized nanoparticles for pharmacological delivery of multimeric glycans, lectins or selective inhibitors of lectin-glycan interactions with antitumor activity.
Insights
Altered cell surface glycans in the tumor microenvironment influence cancer progression. Targeting these glycan-binding proteins (lectins) offers novel therapeutic strategies.
Area of Science:
- Oncology
- Glycobiology
- Immunology
Background:
- Tumor microenvironment exhibits significant changes in glycan-related gene expression.
- Glycosylation alterations impact cancer cells and associated stromal, endothelial, and immune cells.
- Specific glycan changes include branched N-glycans, mucins, and altered sialylation.
Purpose of the Study:
- To review the biological relevance of lectin-glycan interactions in the tumor microenvironment.
- To explore the potential of targeting these interactions for cancer therapy.
- To discuss the design of nanoparticles for delivering therapeutic agents targeting lectin-glycan interactions.
Main Methods:
- Literature review focusing on glycan alterations and lectin-glycan interactions in cancer.
- Analysis of the role of galectin-1 in immunosuppression and angiogenesis.
- Discussion of nanoparticle-based drug delivery strategies for targeting lectin-glycan pathways.
Main Results:
- Glycan alterations in the tumor microenvironment can modulate ligand availability for endogenous lectins.
- Galectin-1 demonstrates immunosuppressive and pro-angiogenic activities within the tumor microenvironment.
- Functionalized nanoparticles offer a platform for delivering multimeric glycans, lectins, or inhibitors.
Conclusions:
- Differential glycan expression presents opportunities for novel cancer biomarkers.
- Targeting lectin-glycan interactions holds therapeutic potential against cancer.
- Nanoparticle-mediated delivery systems can be designed to exploit these interactions for antitumor activity.
Related Concept Videos
Protein Glycosylation
Glycosylation occurs in...
Glycocalyx and its Functions
Glycosaminoglycans
GAGS are found in the extracellular matrix of vertebrates, invertebrates, and bacteria. Due to their polar nature they attract water, and serve as excellent lubricants or shock absorbers in an animal body.
Hyaluronic...
Proteoglycans
Targeted Cancer Therapies
There are several types of targeted therapies against...
Targeted Cancer Therapies

